Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease

Alzheimer's and Dementia

Volumn 10, Issue 5, 2014, Pages S364-S373

  Marek, Gerard J ^a   Katz, David A ^a   Meier, Andreas ^a   Greco, Nicholas ^a   Zhang, Wuyan ^a   Liu, Wei ^a   Lenz, Robert A ^a  

^a ABBVIE INC   (United States)

Author keywords

11 hydroxysteroid dehydrogenase; Alzheimer's disease; Clinical trial; Cognition; Cortisol; Dementia; Donepezil; Enzyme inhibitor; Glucocorticoids; Hypothalamic pituitary adrenal axis

Indexed keywords

ABT 384; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CENTRAL NERVOUS SYSTEM AGENTS; DONEPEZIL; OXIDOREDUCTASE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG; ADAMANTANE; INDAN DERIVATIVE; N-(5-(AMINOCARBONYL)TRICYCLO(3.3.1.13,7)DEC-2-YL)-ALPHA,ALPHA-DIMETHYL-4-(5-(TRIFLUOROMETHYL)-2-PYRIDINYL)-1-PIPERAZINEACETAMIDE; NOOTROPIC AGENT; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ANXIETY DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPIRATION PNEUMONIA; ASSESSMENT OF HUMANS; ASTHENIA; BACKACHE; BALANCE DISORDER; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INCIDENCE; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE INCONTINENCE; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; NEUROPSYCHOLOGICAL TEST;

ADAMANTANE; AGED; ALZHEIMER DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PIPERAZINES; PIPERIDINES; TREATMENT OUTCOME;

EID: 84908248186     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.09.010     Document Type: Article

References (48)

1. C. Courtney, D. Farrell, R. Gray, R. Hills, L. Lynch, and E. Sellwood Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial Lancet 363 2004 2105 2115
2. H. Kavirajan Memantine: a comprehensive review of safety and efficacy Expert Opin Drug Saf 8 2009 89 109
3. R.A. Hansen, G. Gartlehner, A.P. Webb, L.C. Morgan, C.G. Moore, and D.E. Jonas Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Clin Interv Aging 3 2008 211 225
4. B.S. McEwen Central effects of stress hormones in health and disease: understanding the protective and damaging effects of stress and stress mediators Eur J Pharmacol 583 2008 174 185
5. K.L. Davis, B.M. Davis, B.S. Greenwald, R.C. Mohs, A.A. Mathe, and C.A. Johns Cortisol and Alzheimer's disease, I: Basal studies Am J Psychiatry 143 1986 300 305
6. A. Hartmann, J.D. Veldhuis, M. Deuschle, H. Standhardt, and I. Heuser Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared to normal controls: ultradian secretory pulsatility and diurnal variation Neurobiol Aging 18 1997 285 289
7. E.R. Peskind, M.A. Raskind, D. Wingerson, M. Pascualy, L.J. Thal, and D.J. Dobie Hypothalamic-pituitary-adrenocortical axis responses to physostigmine: effects of Alzheimer's disease and gender Biol Psychiatry 40 1996 61 68
8. F.J. Gil-Bea, B. Aisa, A. Solomon, M. Solas, M. del Carmen Mugueta, and B. Winblad HPA axis dysregulation associated to apolipoprotein E4 genotype in Alzheimer's disease J Alzheimers Dis 22 2010 829 838
9. J. Popp, K. Schaper, H. Kolsch, G. Cvetanovska, F. Rommel, and D. Klingmuller CSF cortisol in Alzheimer's disease and mild cognitive impairment Neurobiol Aging 30 2009 498 500
10. K.N. Green, L.M. Billings, B. Roozendaal, J.L., McGaugh, and F.M. LaFerla Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease J Neurosci 26 2006 9047 9056
11. A.M. MacLullich, K.J. Ferguson, L.M. Reid, I.J. Deary, J.M. Starr, and J.M. Wardlaw 11beta-hydroxysteroid dehydrogenase type 1, brain atrophy and cognitive decline Neurobiol Aging 33 2012 e201 e208
12. T.C. Dumas, T. Gillette, D. Ferguson, K., Hamilton, and R.M. Sapolsky Anti-glucocorticoid gene therapy reverses the impairing effects of elevated corticosterone on spatial memory, hippocampal neuronal excitability, and synaptic plasticity J Neurosci 30 2010 1712 1720
13. E.G. Mohler, K.E. Browman, V.A. Roderwald, E.A. Cronin, S. Markosyan, and R. Scott Bitner Acute inhibition of 11beta-hydroxysteroid dehydrogenase type-1 improves memory in rodent models of cognition J Neurosci 31 2011 5406 5413
14. K. Sooy, S.P. Webster, J. Noble, M. Binnie, B.R. Walker, and J.R. Seckl Partial deficiency or short-term inhibition of 11beta-hydroxysteroid dehydrogenase type 1 improves cognitive function in aging mice J Neurosci 30 2010 13867 13872
15. J.L. Yau, K.M. McNair, J. Noble, D. Brownstein, C. Hibberd, and N. Morton Enhanced hippocampal long-term potentiation and spatial learning in aged 11beta-hydroxysteroid dehydrogenase type 1 knock-out mice J Neurosci 27 2007 10487 10496
16. T.C. Sandeep, J.L. Yau, A.M. MacLullich, J. Noble, I.J. Deary, and B.R. Walker 11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics Proc Natl Acad Sci USA 101 2004 6734 6739
17. E.S. Brown Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy Ann NY Acad Sci 1179 2009 41 55
18. A.H. Young, B.J. Sahakian, T.W., Robbins, and P.J. Cowen The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers Psychopharmacology (Berl) 145 1999 260 266
19. M.N. Starkman, B. Giordani, S.S., Gebarski, and D.E. Schteingart Improvement in learning associated with increase in hippocampal formation volume Biol Psychiatry 53 2003 233 238
20. J.N. Hook, B. Giordani, D.E. Schteingart, K. Guire, J. Giles, and K. Ryan Patterns of cognitive change over time and relationship to age following successful treatment of Cushing's disease J Int Neuropsychol Soc 13 2007 21 29
21. W. Liu, D. Katz, C. Locke, D. Daszkowski, Y. Wang, and M. Rieser Clinical safety, pharmacokinetics and pharmacodynamics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers and elderly adults Clin Pharm Drug Dev 2 2013 133 151
22. World Medical Association Declaration of Helsinki Ethical principles for medical research involving human subjects JAMA 284 2000 3043 3045
23. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D., Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 944
24. M.F. Folstein, S.E. Folstein, and P.R. McHugh "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189 198
25. G.S. Alexopoulos, R.C. Abrams, R.C. Young, and C.A. Shamoian Cornell Scale for Depression in Dementia Biol Psychiatry 23 1988 271 284
26. V.C. Hachinski, L.D. Iliff, E. Zilhka, G.H. Du Boulay, V.L. McAllister, and J. Marshall Cerebral blood flow in dementia Arch Neurol 32 1975 632 637
27. W.G. Rosen, R.C. Mohs, and K.L. Davis A new rating scale for Alzheimer's disease Am J Psychiatry 141 1984 1356 1364
28. R.C. Mohs, D. Knopman, R.C. Petersen, S.H. Ferris, C. Ernesto, and M. Grundman Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study Alzheimer Dis Assoc Disord 11(Suppl 2 1997 S13 S21
29. H. Boothby, A., Mann, and A. Barker Factors determining interrater agreement with rating global change in dementia: the CIBIC-plus Int J Geriatr Psychiatry 10 1995 1037 1045
30. J.L. Cummings, M. Mega, K. Gray, S. Rosenberg-Thompson, D.A. Carusi, and J. Gornbein The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia Neurology 44 1994 2308 2314
31. J.L. Cummings The Neuropsychiatric Inventory: assessing psychopathology in dementia patients Neurology 48 Suppl 1997 S10 S16
32. D. Galasko, D. Bennett, M. Sano, C. Ernesto, R. Thomas, and M. Grundman An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study Alzheimer Dis Assoc Disord 11 Suppl 2 1997 S33 S39
33. R.G. Logsdon, L.E. Gibbons, S.M. McCurry, and L. Teri Quality of life in Alzheimer's disease: patient and caregiver reports J Mental Health Aging 5 1999 21 32
34. K. Rickels, F. Garcia-Espana, L.A. Mandos, and G.W. Case Physician Withdrawal Checklist (PWC-20) J Clin Psychopharmacol 28 2008 447 451
35. MedDRA Maintenance and Support Services Organization. Medical dictionary for regulatory activities (MedDRA), version 14.0; 2011.
36. L. Frolich, T. Ashwood, J. Nilsson, and G. Eckerwall Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study J Alzheimers Dis 24 2011 363 374
37. M. Gold, C. Alderton, M. Zvartau-Hind, S. Egginton, A.M. Saunders, and M. Irizarry Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study Dement Geriatr Cogn Disord 30 2010 131 146
38. G. Maher-Edwards, R. Dixon, J. Hunter, M. Gold, G. Hopton, and G. Jacobs SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study Int J Geriatr Psychiatry 26 2011 536 544
39. J., Birks, and R.J. Harvey Donepezil for dementia due to Alzheimer's disease Cochrane Database Syst Rev 1 2006 CD001190
40. J. Birks, J. Grimley Evans, V. Iakovidou, and M. Tsolaki Rivastigmine for Alzheimer's disease Cochrane Database Syst Rev 2 2009 CD001191
41. C., Loy, and L. Schneider Galantamine for Alzheimer's disease and mild cognitive impairment Cochrane Database Syst Rev 1 2006 CD001747
42. R. McShane, A., Areosa Sastre, and N. Minakaran Memantine for dementia Cochrane Database Syst Rev 2 2006 CD003154
43. G. Haig, A. Meier, Y. Pritchett, C. Hall, L., Gault, and R. Lenz Evaluation of the efficacy and safety of the H3 antagonist ABT-288 in mild-to-moderate Alzheimer's disease Alzheimers Dement 8 2012 P601 P602
44. P.S. Aisen, K.L. Davis, J.D. Berg, K. Schafer, K. Campbell, and R.G. Thomas A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study Neurology 54 2000 588 593
45. E.M. Schrijvers, N. Direk, P.J. Koudstaal, C. Kirschbaum, A. Hofman, and H. Tiemeier Associations of serum cortisol with cognitive function and dementia: the Rotterdam Study J Alzheimers Dis 25 2011 671 677
46. P.U. Feig, S. Shah, A. Hermanowski-Vosatka, D. Plotkin, M.S. Springer, and S. Donahue Effects of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome Diabetes Obes Metab 13 2011 498 504
47. S. Shah, A. Hermanowski-Vosatka, K. Gibson, R.A. Ruck, G. Jia, and J. Zhang Efficacy and safety of the selective 11beta-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension J Am Soc Hypertens 5 2011 166 176
48. J. Rosenstock, S. Banarer, V.A. Fonseca, S.E. Inzucchi, W. Sun, and W. Yao The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy Diabetes Care 33 2010 1516 1522